Camizestrant

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerOvarian CancerAdvanced Breast CancerER+ HER2- Advanced Breast CancerEarly Breast Cancer

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Camizestrant

AstraZeneca

Phase 3

12

Adenocard

Astellas

Preclinical

23

Blenoxane

Bristol-Myers Squibb

Preclinical

14

Lexiscan

Astellas

Preclinical

15

Spravato

WWim Janssens

Preclinical

26

Nubain

AAultman Health Foundation

Preclinical

17

Feraheme

AAzurity Pharmaceuticals

Preclinical

18

Duragesic

CCephalon

Preclinical

19

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

110

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1Show 25 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Advanced Breast Cancer2 trials

A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)

Recruiting·AstraZeneca·Phase 2·NCT07427394·24 enrolled

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

Recruiting·AstraZeneca·Phase 3·NCT06380751·788 enrolled

Early Breast Cancer2 trials

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Recruiting·AstraZeneca·Phase 3·NCT05774951·4,300 enrolled

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Active, not recruiting·AstraZeneca·Phase 3·NCT05952557·5,511 enrolled

Hepatic Impairment1 trial

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Completed·AstraZeneca·Phase 1·NCT05790304·22 enrolled

Midazolam1 trial

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

Completed·AstraZeneca·Phase 1·NCT06547164·40 enrolled

Tics1 trial

A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Completed·AstraZeneca·Phase 1·NCT05551897·14 enrolled

4 more indications

Breast Cancer1 trial

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

Not yet recruiting·MMedSIR·Phase 2·NCT07195227·150 enrolled

HER2-negative Breast Cancer1 trial

SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients

Recruiting·AstraZeneca·Phase 3·NCT07647328·150 enrolled

Ovarian Cancer1 trial

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Active, not recruiting·Daiichi Sankyo·Preclinical·NCT04644068·702 enrolled

ER+ HER2- Advanced Breast Cancer1 trial

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Recruiting·AstraZeneca·Preclinical·NCT06188520·564 enrolled

Details

Drug Info

Related News